Search

Search Results

• 

  Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study

  L. Bazzichi, D. Biasi, E. Tinazzi, M. Muratore, R. Pellerito, R. Russo, M. Corsaro Santi, P. De Sandre, O. Epis, M. Granata, B. Kroegler, C. Meschini, F. Versace, C. Astolfi

  224-232

  06-11-2014

  Published: 6 November 2014

  2122

  PDF: 1506

• Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis

  M. Fabris, L. Quartuccio, S. Lombardi, M. Benucci, M. Manfredi, M. Saracco, F. Atzeni, P. Morassi, M.A. Cimmino, E. Pontarini, C. Fabro, R. Pellerito, P. Sarzi-Puttini, M. Cutolo, A. Carletto, L.M. Bambara, F. Fischetti, F. Curcio, E. Tonutti, S. De VIta

  253-258

  Published:

  1965

  PDF: 798

• Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis

  L. Quartuccio, S. Salvin, M. Saracco, S. Lombardi, M. Fabris, E. Mansutti, M. Maset, S. Pellerito, S. De Vita

  182-186

  Published:

  961

  PDF: 664